(EVGN) Evogene Ltd. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EVGN) Evogene Ltd. Complete Analysis Pack
See the Bigger Picture
This Evogene Ltd. BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
CPB platform, 3 divisions
Evogene’s CPB platform is the clearest Star in its BCG mix because it powers three divisions: agriculture, human health, and industrial products. As the core AI-driven discovery engine, it supports nearly every pipeline and sits in a fast-growing market where computational biology keeps attracting more capital and R&D spend. At end-2025, that breadth makes CPB the main strategic asset.
Lavie Bio biocontrols
Lavie Bio biocontrols is a Stars fit for Evogene Ltd. because it targets biological crop inputs, one of the fastest-growing areas in agriculture. Its biostimulants and biocontrols align with the shift away from synthetic chemicals, and a bigger scale could move the unit toward category leadership.
AgPlenus ag-chem discovery
AgPlenus uses CPB to find new herbicide and pesticide candidates, so it sits in Evogene Ltd.’s R&D-heavy "Stars" bucket. The global crop-protection market is still large and expanding, with industry estimates near US$80 billion in 2025, and it keeps rewarding new active ingredients. That mix of strong demand and high innovation keeps AgPlenus’s growth case attractive, even before scale-up.
Biomica microbiome therapeutics
Biomica is a high-growth Star in Evogene Ltd.’s BCG mix: it develops human microbiome therapies for immuno-oncology, gastrointestinal disorders, and antimicrobial resistance. The platform is still pre-commercial, but the addressable need is large; antimicrobial resistance alone was linked to 1.27 million deaths in 2019.
- Pre-commercial, but high upside.
- Targets three major medical markets.
- Best fit for long-term growth bets.
Casterra castor seed platform
Casterra is a "Question Mark" in Evogene Ltd.'s BCG view: it targets improved castor bean seeds for industrial oils, but demand is still niche. The platform can scale if adoption rises in lubricants, coatings, and bio-based chemicals, where castor oil already fits hard-to-replace uses.
It also gives Evogene option value beyond agri and health, but the near-term cash draw is likely bigger than the revenue base.
- Niche market, scalable upside
- Industrial raw-material focus
- Adds portfolio diversification
Evogene’s Growth Engine: CPB, Biocontrols, Crop Protection, and Health
Evogene Ltd.'s Stars are CPB, Lavie Bio, AgPlenus, and Biomica. CPB is the core engine across all units, while Lavie Bio and AgPlenus ride fast-growing biological crop inputs and crop-protection demand near US$80 billion in 2025. Biomica adds high-upside human health exposure, with antimicrobial resistance linked to 1.27 million deaths in 2019.
| Star | Fit | Key number |
|---|---|---|
| CPB | Core platform | Multi-unit use |
| Lavie Bio | Biocontrols | Fast growth |
| AgPlenus | Crop protection | US$80b 2025 |
| Biomica | Human health | 1.27m deaths |
What is included in the product
Detailed Word Document
Evogene Ltd. BCG Matrix maps its biotech units by growth and market share to guide invest, hold, or divest decisions.
Editable Excel File
Quick BCG snapshot of Evogene Ltd. to identify winners, cash traps, and where to focus capital.
Reference Sources
Evogene Ltd. Reference Sources add credibility and help decisions by tracing key claims to clear, trusted evidence.
Cash Cows
No true cash cow
Evogene Ltd. has no true cash cow because it is still largely pre-commercial and does not yet have a mature, high-share product engine. Its closest cash generation comes from collaboration funding and milestone receipts, which can support R&D and overhead without building a heavy direct-sales force. That fits a BCG matrix profile of no stable cash-generating unit yet.
BASF collaboration cash
BASF is a cash cow for Evogene Ltd. because the collaboration can deliver upfront, milestone, and program-support fees, so it funds R&D without the same risk as new product launches. Evogene reported a cash balance of about $12.5 million at year-end 2024, so external cash like this matters. BASF’s 2025 sales were about €65 billion, which shows the partner’s scale and funding capacity.
Corteva collaboration cash
Corteva remains one of Evogene Ltd.’s most important ag partners, so this cash stream is a classic Cash Cow: it lowers commercialization risk and helps fund ongoing discovery. Large-partner deals like this are usually milestone- and collaboration-based, which makes the inflow steadier than early-stage product bets and supports Evogene’s platform work.
Bayer collaboration cash
Bayer’s scale gives Evogene a strong validation signal: Bayer reported about €46.6bn in 2024 sales, with Crop Science near €22.3bn. That kind of partner cash is steadier than early product sales, so it works more like a funding engine than a brand bet. For Evogene, this is classic Cash Cow support for the ag platform.
- Bayer boosts platform credibility.
- Revenue is steadier than product sales.
- Cash supports R&D and runway.
Milestones and licensing fees
Evogene’s closest thing to a cash cow is milestone and licensing income, because it can monetize programs without carrying the full cost of product buildout or marketing. In its 2024 filings, this kind of capital-light revenue still sat alongside a small top line, so every signed deal matters more than product sales. The upside is repeatable; the downside is it depends on partner progress.
- Milestones drive recurring cash capture
- Licensing fees avoid heavy product spend
- Partner success triggers future payments
- Cash flow stays tied to deal flow
Evogene’s Closest Cash Cows: BASF, Bayer, and Corteva
Evogene Ltd. has no true cash cow, because 2025 revenue still depends on partner funding, milestones, and licensing rather than a mature product franchise. Its closest cash inflows come from BASF, Bayer, and Corteva collaborations, which help fund R&D and lower burn. Evogene’s year-end 2024 cash was about $12.5 million, so these receipts matter for runway.
| Source | Why it acts like cash cow | Latest data |
|---|---|---|
| BASF | Milestone and support fees | 2025 sales about €65 billion |
| Bayer | Steady partner funding | 2024 sales about €46.6 billion |
| Corteva | Recurring collaboration cash | Large ag platform partner |
Preview the Actual Deliverable
Evogene Ltd. Reference Sources
The Evogene Ltd. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content, no watermarks—just the full, professionally formatted report. Once purchased, it’s ready for immediate download, editing, or presentation. What you preview is what you get.
Dogs
Medical cannabis products
Medical cannabis products sit in a fragmented, price-pressured market, with no clear share leader and thin margins across many operators. Evogene Ltd.'s cannabis-related efforts have not shown dominant market share, so this line fits the Dog bucket better than a Star. That makes it a low-growth, low-share bet with limited evidence of scale.
Canonic and Cannbit JV
Canonic and Cannbit JV is still a Dogs item in Evogene Ltd. BCG Matrix terms because it has not turned into a material earnings driver. Cannabis rules stay fragmented across markets, and the venture has not reached the scale needed to lift returns. If growth and market share do not improve in 2026, it should remain a weak portfolio asset.
Direct cannabis sales
Evogene Ltd.'s direct cannabis sales fit a Dog in BCG terms: the market is crowded, and U.S. legal cannabis sales were about $30 billion in 2024, yet price cuts and distribution costs keep margins thin. The business has not shown the scale needed for leadership, so it looks more like a management drag than a growth engine.
Legacy non-core pilots
Legacy non-core pilots at Evogene Ltd. look like Dogs because they sit outside the main agriculture and health engines and have weak scale economics. These projects can drain time and cash, and unless a partner or buyer appears, they are hard to justify as long-term growth assets.
- Low market impact
- Capital and time drain
- Weak scale proof
- Best cut, sell, or partner
Small stand-alone launches
Small stand-alone launches fit Dogs: they often lack the channel reach needed to win share, and Evogene Ltd. still looks more platform-led than product-led. In 2025, the company’s value case stayed tied to its AI and seed-tech platforms, not to one-off launches, so small products without traction should be treated as non-core. If a launch cannot scale fast, it usually burns cash before it builds share.
- Weak channel support hurts scale.
- Platform assets drive Evogene Ltd.'s edge.
- Small launches should stay non-core.
Evogene’s Cannabis Bets Remain Small, Weak, and Hard to Scale
Evogene Ltd.'s Dogs are cannabis and other non-core pilots: they show weak share, thin margins, and little earnings pull. U.S. legal cannabis sales reached about $30 billion in 2024, but Evogene Ltd. has not built scale to turn that market into value. These units still look best for cut, sell, or partner.
| Dog | Why it fits | Action |
|---|---|---|
| Cannabis | Low share, thin margins | Cut or partner |
| Small launches | No scale proof | Keep non-core |
Question Marks
Biomica lead candidates
Biomica’s lead candidates sit in a microbiome therapeutics market valued at about $1.3 billion in 2024, with forecasts often calling for 20%+ annual growth through 2030. The science is promising, but low clinical and commercial proof keeps share small. To move from question marks to stars, Biomica needs more capital or a strong partner.
Immuno-oncology assets
Evogene Ltd.'s Biomica immuno-oncology assets fit the Question Marks box: the field is one of the biggest growth areas in health care, but the programs are still early and not yet commercial. That means the upside is large, while execution risk stays high, especially in a sector where oncology drug success rates are usually low. If Biomica converts even one program into late-stage data, the value shift could be material.
GI disorder assets
Microbiome therapies for gastrointestinal disorders are in a growing market, but Evogene Ltd.’s GI assets are still early stage. The global IBS market alone is forecast in the billions, while GI disease burden remains high, so the upside is real. Still, with limited late-stage proof and no clear revenue base, this fits a question mark, not a cash generator.
AMR infection assets
AMR is a huge unmet need: WHO says antimicrobial resistance may drive 10 million deaths a year by 2050, so the market is real, but Evogene Ltd.’s AMR infection assets still have near-zero share because they are pre-commercial.
The upside is tied to proof, not promise: microbiome-based programs need clinical validation, regulatory clearance, and a strong partner to fund trials and scale. Until then, this stays a question mark in the BCG matrix.
- High-need, high-upside market
- Current share: effectively zero
- Value depends on trials and partners
Crop-trait pipeline, 5 crops
Evogene’s crop-trait pipeline covers corn, soybean, wheat, rice, and cotton, five of the world’s biggest seed markets, but it is still a question mark because trait adoption is unproven. Global row-crop seed and trait demand is large and still growing, yet the value only converts if Evogene turns R&D into licensed products, field data, and paid launches.
- Big market, weak proof of adoption.
- Five crops raise upside, but also risk.
- Commercial wins are the key test.
Until those programs move into signed deals or revenue, the pipeline stays a capital-intensive bet rather than a cash engine. A single successful trait launch could shift it fast, but without conversion, it remains in question-mark status.
Evogene’s High-Risk, High-Upside Question Marks
Evogene Ltd.’s Question Marks are early-stage, high-upside bets: Biomica’s market is about $1.3 billion in 2024, and AMR could cause 10 million deaths a year by 2050, but revenue is still near zero. Crop traits also span five major crops, yet adoption is unproven, so value still depends on trials, partners, and funding.
| Area | Status | Key number |
|---|---|---|
| Biomica | Question Mark | $1.3B market |
| AMR | Question Mark | 10M deaths by 2050 |
| Crop traits | Question Mark | 5 crops |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.